Zack Williams is an M.D./Ph.D. student at Vanderbilt University, in Nashville, Tennessee, currently pursuing a joint Ph.D. in neuroscience and hearing and speech sciences. His research focuses on the development and evaluation of psychological measures for use in adults on the autism spectrum. He is particularly interested in the assessment of co-occurring psychiatric and psychosomatic disorders in autistic adults and the development of evidence-based treatments for these conditions.
Zachary Williams
M.D./Ph.D. student
Vanderbilt University
From this contributor
Common sensory response scores may miss important variations
A person’s “overall” score on sensory-seeking, hyperreactive or hyporeactive tendencies may obscure nuances in their individual sensory experience.
Common sensory response scores may miss important variations
By
Zachary Williams, Tiffany Woynaroski
22 February 2024 | 5 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read